These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27237318)

  • 41. Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer.
    Sakamoto K; Imai K; Higashi T; Taki K; Nakagawa S; Okabe H; Nitta H; Hayashi H; Chikamoto A; Ishiko T; Beppu T; Baba H
    Cancer Sci; 2015 Sep; 106(9):1153-62. PubMed ID: 26132727
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased S100A4 expression combined with decreased E-cadherin expression predicts a poor outcome of patients with pancreatic cancer.
    Oida Y; Yamazaki H; Tobita K; Mukai M; Ohtani Y; Miyazaki N; Abe Y; Imaizumi T; Makuuchi H; Ueyama Y; Nakamura M
    Oncol Rep; 2006 Sep; 16(3):457-63. PubMed ID: 16865243
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GALNT6, GALNT14, and Gal-3 in association with GDF-15 promotes drug resistance and stemness of breast cancer
    Gadwal A; Purohit P; Khokhar M; Vishnoi JR; Pareek P; Choudhary R; Elhence P; Banerjee M; Sharma P
    Growth Factors; 2024 May; 42(2):84-100. PubMed ID: 38889447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling.
    Huang MJ; Hu RH; Chou CH; Hsu CL; Liu YW; Huang J; Hung JS; Lai IR; Juan HF; Yu SL; Wu YM; Huang MC
    Oncotarget; 2015 Mar; 6(8):5650-65. PubMed ID: 25730904
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9.
    Hamada S; Satoh K; Fujibuchi W; Hirota M; Kanno A; Unno J; Masamune A; Kikuta K; Kume K; Shimosegawa T
    Mol Cancer Res; 2012 Jan; 10(1):3-10. PubMed ID: 22064652
    [TBL] [Abstract][Full Text] [Related]  

  • 46. C-terminal tensin-like gene functions as an oncogene and promotes cell motility in pancreatic cancer.
    Al-Ghamdi S; Cachat J; Albasri A; Ahmed M; Jackson D; Zaitoun A; Guppy N; Otto WR; Alison MR; Kindle KB; Ilyas M
    Pancreas; 2013 Jan; 42(1):135-40. PubMed ID: 22750970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of PPM1H on malignant phenotype of human pancreatic cancer cells.
    Zhu H; Qin H; Li DM; Liu J; Zhao Q
    Oncol Rep; 2016 Nov; 36(5):2926-2934. PubMed ID: 27599670
    [TBL] [Abstract][Full Text] [Related]  

  • 48. E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma in mice.
    Stark AP; Chang HH; Jung X; Moro A; Hertzer K; Xu M; Schmidt A; Hines OJ; Eibl G
    Surgery; 2015 Dec; 158(6):1564-72. PubMed ID: 26297056
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transcriptional silencing of ETS-1 abrogates epithelial-mesenchymal transition resulting in reduced motility of pancreatic cancer cells.
    Li C; Wang Z; Chen Y; Zhou M; Zhang H; Chen R; Shi F; Wang C; Rui Z
    Oncol Rep; 2015 Feb; 33(2):559-65. PubMed ID: 25421630
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MUC4-induced nuclear translocation of β-catenin: a novel mechanism for growth, metastasis and angiogenesis in pancreatic cancer.
    Zhi X; Tao J; Xie K; Zhu Y; Li Z; Tang J; Wang W; Xu H; Zhang J; Xu Z
    Cancer Lett; 2014 Apr; 346(1):104-13. PubMed ID: 24374017
    [TBL] [Abstract][Full Text] [Related]  

  • 51. B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells.
    Qian Y; Hong B; Shen L; Wu Z; Yao H; Zhang L
    Cell Tissue Res; 2013 Jul; 353(1):139-51. PubMed ID: 23660627
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines.
    Menke A; Philippi C; Vogelmann R; Seidel B; Lutz MP; Adler G; Wedlich D
    Cancer Res; 2001 Apr; 61(8):3508-17. PubMed ID: 11309315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer.
    Ohtsubo K; Yamada T; Zhao L; Jin TF; Takeuchi S; Mouri H; Yamashita K; Yasumoto K; Fujita N; Kitagawa H; Ohta T; Ikeda H; Yano S
    Pancreas; 2014 Oct; 43(7):1093-100. PubMed ID: 25036909
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells.
    Koenig A; Mueller C; Hasel C; Adler G; Menke A
    Cancer Res; 2006 May; 66(9):4662-71. PubMed ID: 16651417
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RNAi knockdown of Hop (Hsp70/Hsp90 organising protein) decreases invasion via MMP-2 down regulation.
    Walsh N; Larkin A; Swan N; Conlon K; Dowling P; McDermott R; Clynes M
    Cancer Lett; 2011 Jul; 306(2):180-9. PubMed ID: 21470770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PKM2 gene regulates the behavior of pancreatic cancer cells via mitogen-activated protein kinase pathways.
    Feng J; Ma T; Ge Z; Lin J; Ding W; Chen H; Zhu W; Zhou S; Tan Y
    Mol Med Rep; 2015 Mar; 11(3):2111-7. PubMed ID: 25411978
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells.
    Cheng JC; Chang HM; Leung PC
    Oncogene; 2013 Feb; 32(8):1041-9. PubMed ID: 22508482
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Crosstalk between Nrf2 and TGF-β1 in the Epithelial-Mesenchymal Transition of Pancreatic Duct Epithelial Cells.
    Arfmann-Knübel S; Struck B; Genrich G; Helm O; Sipos B; Sebens S; Schäfer H
    PLoS One; 2015; 10(7):e0132978. PubMed ID: 26226105
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Knockdown of ribosomal protein L39 by RNA interference inhibits the growth of human pancreatic cancer cells in vitro and in vivo.
    Li C; Chen D; Luo M; Ge M; Zhu J
    Biotechnol J; 2014 May; 9(5):652-63. PubMed ID: 24799381
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early-Stage Loss of GALNT6 Predicts Poor Clinical Outcome in Colorectal Cancer.
    Ogawa M; Tanaka A; Namba K; Shia J; Wang JY; Roehrl MH
    Front Oncol; 2022; 12():802548. PubMed ID: 35692787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.